<DOC>
	<DOCNO>NCT00739830</DOCNO>
	<brief_summary>The purpose study compare progression-free survival ( PFS ) patient advance , recurrent metastatic endometrial cancer receive one , two , prior line chemotherapy either adjuvant therapy treatment advance disease , treat ridaforolimus investigator ' choice progestin chemotherapy .</brief_summary>
	<brief_title>Clinical Trial Ridaforolimus Compared Progestin Chemotherapy Advanced Endometrial Carcinoma ( MK-8669-007 AM6 )</brief_title>
	<detailed_description />
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<mesh_term>Medroxyprogesterone</mesh_term>
	<mesh_term>Megestrol</mesh_term>
	<mesh_term>Medroxyprogesterone Acetate</mesh_term>
	<mesh_term>Megestrol Acetate</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Progestins</mesh_term>
	<criteria>18 year age older Endometrial cancer Patients must treat least one line chemotherapy , two line chemotherapy , experience progressive disease At least one measurable lesion ECOG performance status less equal 1 Minimum life expectancy 3 month Adequate renal hepatic function Adequate bone marrow function Serum cholesterol &lt; 350 mg/dL triglyceride &lt; 400 mg/dL Able understand give write informed consent Females childbearing potential must negative pregnancy test use approve contraception screen 30 day last study drug give Two line chemotherapy recurrent metastatic disease Chemotherapy recurrent metastatic disease administer within six month adjuvant therapy More two line chemotherapy type Prior therapy hormonal agent Women pregnant lactate Presence brain central nervous system metastases Prior therapy rapamycin , rapamycin analogue tacrolimus know sensitivity agent Anticancer treatment ( chemotherapy , radiotherapy ) within 4 week prior randomization Ongoing toxicity associate prior anticancer therapy Inadequate recovery prior surgical procedure undergone major surgical procedure within 2 week prior randomization . Another primary malignancy within past five year ( except nonmelanoma skin cancer cervical carcinoma situ ) Known Grade 3 4 hypersensitivity macrolide antibiotic Significant uncontrolled cardiovascular disease Active infection Known HIV infection Known Hepatitis B C infection Newly diagnose ( within 3 month enrollment ) poorly control Type 1 2 diabetes Concurrent treatment immunosuppressive agent A requirement concurrent treatment medication strongly induce inhibit cytochrome P450 ( CYP3A )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>